Abstract:Background: Glioblastoma (GBM) is the most malignant primary brain tumor with a median survival of 15 months despite aggressive multimodal treatment. There is an urgent need for novel drug discovery for GBM. CSPG4/NG2 transmembrane proteoglycan is a validated target, upregulated in 50% of GBM patient tumours, drives malignant progression and is independently prognostic for poor survival. We have recently identified a cancer specific 13 bp frameshift deletion in the CSPG4/NG2 gene (CSPG4/NG2del13), which leads to reduced protein expression and slowed cell growth in vitro and tumor take in vivo. The 3D structure of CSPG4/NG2 has not yet been solved, and unsuited for structure prediction by AlphaFold2 due to its size and PTMs. The structure of CSPG4/NG2 domain 1 (residues 411-547), containing the site of the 13 bp deletion, has been solved using cryo-EM and can be useful for new drug design. We hypothesize that a small-molecule inhibitor that binds to this 13 bp region of the CSPG4/NG2 proteoglycan, might induce the same phenotype as the 13 bp deletion. Methods: Using the published structure of domain 1, we performed in silico analysis to predict binding sites and docked 1280 compounds from the Prestwick Chemical library's database of FDA-approved drugs to these sites. The high ranked hits were further tested in vitro in GBM cells. Clonogenic survival, cell proliferation and scratch-wound assays were performed in patient derived P3, A172 and in CSPG4/NG2del13 heterozygous (HZ) GBM cells, that served as controls. Results: Three binding sites were found in the close proximity to the 13 bp deletion region within the N-terminal domain 1 of CSPG4/NG2. Docking analysis revealed multiple drug candidates bound to the predicted binding site, three of which were further analyzed. Dopamine is found to closely interact with CSPG4/NG2 domain 1, near the 13 bp deletion site, forming hydrogen bonds with Glu413 and Glu521. Pyrazinamide forms two hydrogen bonds with Glu521. 5-Azacytidine fits well into active site 1, establishing hydrogen bonds with key residues Gly475, Glu482, Val472 and Thr473. The in vitro functional assays showed that the top hits have a dose dependent negative effect on colony formation and cell proliferation in P3 and A172 GBM cells (P < 0.0001). The treatment with the same drug IC50 doses led to a growth rescue in the CSPG4/NG2del13 HZ cells compared to the WT cells (P < 0.001). 5-Azacytidine showed a significant inhibitory effect (P < 0.0001) on cell migration in P3, A172 GBM cells and also in HZ cells, (P < 0.001). Conclusion: The residues spanning the site of 13 bp deletion have chemical motifs that are salient for docking small molecule inhibitors that disrupt CSPG4/NG2 function. N-terminus domain 1 and full-length CSPG4/NG2 proteins for Cryo-EM 3D structure determination are being used to interrogate biochemical kinetics and identify new target regions. Citation Format: Lasse Neset, Mia Kristin Nilsen, Victoria Smith Arnesen, Kazi Asraful Alam, Martha Chekenya, Mohummad Aminur Rahman. Cryo-EM structure-based small molecule inhibitor drugs targeting CSPG4/NG2 in glioblastoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 4494.

New natural compound inhibitors of PDGFRA (platelet-derived growth factor receptor α) based on computational study for high−grade glioma therapy

Identification of Imidazo[4,5-C]pyridin-2-one Derivatives As Novel Src Family Kinase Inhibitors Against Glioblastoma.

Screening and Analysis of Possible Drugs Binding to PDGFRα: A Molecular Modeling Study

Novel Natural Inhibitors for Glioblastoma by Targeting Epidermal Growth Factor Receptor and Phosphoinositide 3-kinase

Design, synthesis and evaluation of novel pyrimidinylaminothiophene derivatives as FGFR1 inhibitors against human glioblastoma multiforme

Silico analysis of the target and possible mechanism of lomustine in the treatment of primary glioblastoma

Identification of novel small-molecule inhibitors of glioblastoma cell growth and invasion by high-throughput screening.

Identification of potential bioactive phytochemicals for the inhibition of platelet-derived growth factor receptor β: a structure-based approach for cancer therapy

Multitarget Potential Drug Candidates for High-Grade Gliomas Identified by Multiple Reaction Monitoring Coupled with In Silico Drug Repurposing

Discovery of Novel Small-Molecule-Based Potential PD-L1/EGFR Dual Inhibitors with High Druggability for Glioblastoma Immunotherapy

Effective Natural Inhibitors Targeting IGF-1R by Computational Study

Discovery of Small-Molecule Inhibitors of the HSP90-Calcineurin-NFAT Pathway Against Glioblastoma.

Design, synthesis and biological evaluation of 5-amino-1H-pyrazole-4-carboxamide derivatives as pan-FGFR covalent inhibitors

A molecular screening approach to identify and characterize inhibitors of glioblastoma stem cells

Design, synthesis and biological evaluation of pyrazolo[3,4-d]pyridazinone derivatives as covalent FGFR inhibitors

Exploration of 2D and 3D-QSAR analysis and docking studies for novel dihydropteridone derivatives as promising therapeutic agents targeting glioblastoma

Design, Synthesis, and Biological Evaluation of Covalent Inhibitors of Focal Adhesion Kinase (FAK) against Human Malignant Glioblastoma

The induction of potent anti-tumor efficacy in diffuse intrinsic pontine glioma by YF-PRJ8-1011 of a novel cyclin-dependent kinase 4/6 inhibitor

Pharmacogenomic Analysis of Combined Therapies against Glioblastoma Based on Cell Markers from Single-Cell Sequencing

Abstract 4494: Cryo-EM structure-based small molecule inhibitor drugs targeting CSPG4/NG2 in glioblastoma

Identification of novel PHGDH inhibitors based on computational investigation: an all-in-one combination strategy to develop potential anti-cancer candidates